Leica Microsystems announces the introduction of the Novocastra™ HD antibody range, 80 clinically important immunohistochemistry antibody clones, spanning 10 anatomical pathologies

Novocastra HD was developed to meet the needs of pathologists and histologists, in terms of menu, diagnostic confidence and workflow. This new ‘Highly Definitive’ range was created following extensive global market research on customer preferences, combined with the results of a comprehensive competitive evaluation* of each antibody by NordiQC. The Novocastra HD menu therefore represents antibodies with independently qualified performance, each available in a range of new sizes and formats aligned to laboratory workloads.

‘When it comes to patient diagnosis, we know that excellence in staining quality isn’t an option - it’s an essential requirement’, says Arnd Kaldowski, President of Leica Biosystems. ‘We ensured the optimized performance of each and every product and have compared performance on BOND with other leading clones in the market on competitive IHC stainers. The new Novocastra HD range represents our new trusted standard in the selection of high performing antibodies.’

The Novocastra HD range will be available for sale in the USA and EU from August 2012, commencing with the breast pathology menu. Leica Microsystems plans to release a further nine disease specific ranges in 2012 and 2013.

*Independent evaluation by NordiQC according to the manufacturers‘ instructions for use, commissioned by Leica Microsystems

For more information about the The Novocastra HD range click here